Ø Heterogeneity in mortality rates reported was quantified in terms of the Q-and I2-statistics. The Q-statistics is based on the chi-squared test and assesses deviation between individual study effect and the pooled effect across studies. A large Qvalue relative to its degree of freedom provides evidence of heterogeneity of outcome measured (variation in outcome estimates beyond chance). The I 2 -statistics describes the percentage of the variability in outcome estimates that is due to heterogeneity rather than sampling error (chance).
Ø Key study characteristics, including patient population, sample size, setting, and therapies were extracted to identify potential reasons for variability in mortality reports.
Ø Predictors of all-cause mortality and proportions of deaths related to MAC lung disease were also analyzed. 
Results
Ø This research found that majority of the identified studies showed poor long-term survival in patients with MAC lung disease. Particularly in patients with cavities, MAC lung disease considerably contributed to the all-cause mortality.
Ø The wide range of mortality rates reported, however, suggests presence of heterogeneity in the rate of all-cause mortality, likely driven by differences in patient characteristics and patient management.
Ø Reported predictors of all-cause mortality are likely population-specific and thus have varying relevance for mortality. Also, not all factors found as predictors in one study were measured in other studies, thus making comparison across studies difficult. Nevertheless, some commonalities can be observed, particularly high co-morbidity levels and presence of cavities as negative prognostic factors.
Ø A limitation of the study is that we searched for studies included in the MEDLINE database only. Therefore, the identified list of relevant studies may not be fully comprehensive.
Ø Additionally, we did not exclude studies according to a set of stringent, pre-specified criteria, hence the results of this meta analysis are likely to be influenced by the study design and quality of the published reports.
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Conclusions
Ø Risk of all-cause mortality in patients with MAC lung disease varies across studies. Most of the studies document a 5-year mortality rate greater than 25%, indicating a substantial health threat to people with the disease.
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